Department of Internal Medicine, Division of Rheumatology, Namazee Hospital, Shiraz University of Medical Sciences, Shiraz, Iran.
Molecular Dermatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Clin Rheumatol. 2022 Jan;41(1):95-104. doi: 10.1007/s10067-021-05900-7. Epub 2021 Sep 1.
Systemic sclerosis (SSc) is a systemic multi-organ disease. Raynaud's phenomenon (RP) and digital ulcers (DUs) in SSc patients can be resistant to usual treatments. We studied the clinical benefits, capillaroscopy changes, and cost-effectiveness of local injection of botulinum toxin-A (BTX-A) and intravenous prostaglandin analogs (iloprost/alprostadil) in patients with SSc with resistant DUs.
In a clinical trial study, we evaluated 26 patients fulfilling the ACR/EULAR SSc criteria with resistant DUs. Visual analog scale of pain and RP, skin color and type of ulcers, and capillaroscopy were assessed before and 1 month after treatment. In the first group, 20 units of BTX-A was injected at the base of each involved fingers by a dermatologist. In the second group, 20 µg iloprost or 60 µg alprostadil was infused daily. The cost of these treatments was compared.
In 26 patients (43 fingers), there were 16 patients (22 fingers) in the BTX-A and 10 patients (21 fingers) in the prostaglandin group. In 95.5% of the BTX-A and 90.5% of the prostaglandin group, the ulcers were healed. In both groups, a significant decrease in pain was seen (p < 0.0001). Capillaroscopy patterns in both groups were not changed although the microhemorrhages disappeared significantly (p value: BTX-A: 0.03 and prostaglandin: 0.002). The cost was significantly lower in the BTX-A injection group (p < 0.0001).
Both BTX-A and prostaglandins helped in the healing and pain control of DUs. In capillaroscopy, microhemorrhages were significantly decreased in both groups. In the BTX-A group, the cost was significantly lower as an outpatient treatment and was more time-saving.
• BTX-A and prostaglandin analogs both contributed to the healing of digital tip ulcers and improving the pain • In capillaroscopy, microhemorrhages were significantly decreased or disappeared after both treatments • There was no significant side effect in both groups • Comparing both groups, in the BTX-A group, the cost was significantly lower when performed on an outpatient treatment and more time-saving.
系统性硬化症(SSc)是一种全身性多器官疾病。SSc 患者的雷诺现象(RP)和指端溃疡(DU)可能对常规治疗有抗性。我们研究了局部注射肉毒杆菌毒素-A(BTX-A)和静脉内前列腺素类似物(前列环素/前列腺素 E1)在具有抗性 DU 的 SSc 患者中的临床益处、毛细血管镜变化和成本效益。
在临床试验研究中,我们评估了 26 名符合 ACR/EULAR SSc 标准且具有抗性 DU 的患者。在治疗前和治疗后 1 个月评估疼痛和 RP 的视觉模拟量表、皮肤颜色和溃疡类型以及毛细血管镜。在第一组中,由皮肤科医生在每个受累手指的根部注射 20 单位 BTX-A。在第二组中,每天输注 20μg前列环素或 60μg前列腺素 E1。比较这些治疗的费用。
在 26 名患者(43 个手指)中,BTX-A 组有 16 名患者(22 个手指),前列腺素组有 10 名患者(21 个手指)。在 95.5%的 BTX-A 和 90.5%的前列腺素组中,溃疡愈合。在两组中,疼痛均显著减轻(p<0.0001)。尽管微出血明显减少,但两组的毛细血管镜模式均未改变(p 值:BTX-A:0.03 和前列腺素:0.002)。BTX-A 注射组的费用明显较低(p<0.0001)。
BTX-A 和前列腺素均有助于 DU 的愈合和疼痛控制。在毛细血管镜下,两组的微出血均明显减少。在 BTX-A 组中,由于门诊治疗且更省时,费用明显降低。
• BTX-A 和前列腺素类似物均可促进指尖溃疡愈合并改善疼痛• 在毛细血管镜下,两种治疗后微出血均显著减少或消失• 两组均无明显副作用• 与两组相比,BTX-A 组在门诊治疗时费用显著降低且更省时。